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Abstract
Background: Type 2 diabetes (T2D) is projected to affect 439 million people by 2030. Medical management
focuses on controlling blood glucose levels pharmacologically in a disease that is closely related to lifestyle factors
such as diet and inactivity. Physical activity guidelines include aerobic exercise at intensities or volumes potentially
unreachable for older adults limited by many co-morbidities. We aim to show for the first time the efficacy of a
novel exercise modality, power training (high-velocity, high-intensity progressive resistance training or PRT), in older
adults with T2D as a means for improving glycemic control and targeting many associated metabolic and
physiological outcomes.
Eligibility criteria included community-dwelling men and women previously diagnosed with T2D who met the
current definition of metabolic syndrome according to the International Diabetes Federation. Participants were
randomized to a fully supervised power training intervention or sham exercise control group for 12 months.
Intervention group participants performed whole body machine-based power training at 80%1RM, 3 days per week.
The control group undertook the same volume of non-progressive, low-intensity training. Participants were
assessed at baseline, 6 months and 12 months and followed for a further 5 years, during which time participants
were advised to exercise at moderate-high intensity. Glycemic control (HbA1c) and insulin resistance as measured
by the homeostatic model assessment 2 (HOMA2-IR) were the primary outcomes of the trial. Outcome assessors
were blinded to group assignment and participants were blinded to the investigators’ hypothesis regarding the
most effective intervention.
Results: We recruited 103 participants (48.5 % women, 71.6 ± 5.6 years). Participants had 5.1 ± 1.8 chronic diseases,
had been diagnosed with T2D for 8 ± 6 years and had a body mass index (BMI) of 31.6 ± 4.0 kg/m2. Fasting glucose
and insulin were 7.3 ± 2.4 mmol/L and 10.6 ± 6.3 mU/L, respectively. HbA1c was 54 ± 12 mmol/mol. Eighty-six
participants completed the 12-month assessment and follow-up is ongoing. This cohort had a lower-than-expected
dropout (n = 14, 14 %) over the 12-month intervention period.
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Conclusions: Power training may be a feasible adjunctive therapy for improving glycemic control for the growing
epidemic of T2D in older adults.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12606000436572 (24 September 2006).
Keywords: Type 2 diabetes, Resistance training, Weight lifting, Randomized controlled trial, Power training
Background
Physical activity is a critical component of optimal man-
agement for the increasing epidemic of type 2 diabetes
(T2D) [1]. Although not as well studied as aerobic exer-
cise in this cohort [2], progressive resistance training
(PRT) has been shown to improve glucose homeostasis
in T2D, with a clinically relevant effect size (ES) not sig-
nificantly different from aerobic exercise or combined
exercise or lifestyle programs [3]. It may also improve
blood pressure, dyslipidemia, markers of inflammation
and catabolism, and visceral obesity, thus addressing
many components of metabolic syndrome [4–6]. Add-
itionally, PRT has beneficial effects on functional exer-
cise capacity [7, 8], osteoarthritis [9], bone health [10],
depression and insomnia [11], and cognitive impairment
[12], thus addressing many common co-morbidities in
older adults with T2D and obesity. Importantly, PRT, in
contrast to aerobic exercise, attenuates or prevents the
loss of lean tissue accompanying dietary weight loss [13],
thus addressing the potential adverse metabolic and clin-
ical effects such a loss of muscle and bone mass may
produce [14].
Resistance training is commonly recommended at
moderate intensity and slow velocity for older adults
[15]. By contrast, power training typically involves push-
ing a weight as quickly as possible during the concentric
phase and slowly returning the weight to the start pos-
ition during the eccentric phase [16]. As the rate of de-
cline in power is greater than the rate of decline in
strength with aging [17], power training may be particu-
larly important to older adults, and has notably been
shown to be more effective in improving physical func-
tion [18] and maintaining bone density [19] as compared
to conventional slow-velocity resistance training. Power
training has also been shown to improve functional tasks
such as standing up from a chair, climbing stairs [20]
and gait speed [21]. Moreover, power training specific-
ally targets the type 2b muscle fiber atrophy that pre-
dominates in older adults and contributes to sarcopenia
[22–24]. Power training thus has the potential to provide
a broader spectrum of benefit than slow-velocity PRT,
yet this alternative form of PRT has never been directly
tested as a strategy to treat individuals with diabetes and
metabolic syndrome.
With any new therapy, it is important to establish the
overall risk/benefit ratio, rather than just focus upon the
effect on the target symptom. Thus, our measures of
other clinical problems in these individuals with meta-
bolic syndrome, such as muscle weakness, immobility,
disability, depression, cognitive impairment, sleep dis-
turbance, postural and post-prandial hypotension, and
cardiovascular symptoms will provide a balanced per-
spective on the unique benefits and risks of this thera-
peutic approach compared to usual care. It is also
critically important to establish the utility of this inter-
vention on its own, before combining it with other
interventions such as weight loss diets, or aerobic exer-
cise [4, 25] so that the independent contribution of
power training to diabetes and metabolic syndrome can
be definitively established.
Objectives
Our specific aim was to conduct a 12-month random-
ized controlled trial (RCT) to test the efficacy of power
training added to the usual medical care of older adults
with T2D and metabolic syndrome. In addition, the
long-term feasibility and benefits of this type of exercise
will be assessed over 6 years of follow-up.
Primary hypothesis
Power training will be associated with sustained im-
provements in insulin sensitivity and HbA1c compared
to the sham exercise control group at 6-month and 12-
month follow-up.
Secondary hypotheses
1. Power training will be associated with improvements
in the other components of metabolic syndrome and
cardiovascular risk associated with T2D, including:
increased circulating high-density lipoprotein (HDL)
cholesterol, decreased total and low-density lipopro-
tein (LDL) cholesterol and triglyceride (TG) levels,
decreased ambulatory blood pressure, increased aer-
obic capacity, improved heart rate variability and
postural hypotension compared to the sham exercise
control condition.
2. Power training will be associated with a significant
reduction in visceral adiposity and intramuscular
lipid and increase in regional and whole body
measures of lean muscle mass, bone mineral density,
function, and metabolism, as well as a shift in the
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anabolic milieu (decreased circulating and adipose
tissue levels of inflammatory/catabolic cytokines and
increased anabolic/anti-inflammatory factors)
compared to the sham exercise control condition.
3. Body composition changes across the entire cohort
will be related to observed metabolic/inflammatory
improvements, whereas total body mass changes will
not.
4. Randomization to the power training intervention as
well as higher levels of participation in structured
physical activity during follow-up will predict better
outcomes in the above primary and secondary do-




Hypothesized differences between the experimental and
control participants for the primary outcomes drove
sample size estimates of insulin resistance and HbA1c,
based on published studies of PRT in diabetes/obesity
[6, 26]. Largest available standard deviations were used
for conservative estimates of ES. The most comprehen-
sive meta-analysis at the time of study planning [27] in-
dicated that control participants in enrolled exercise
trials did not improve in metabolic outcomes, thus the
control change was set at 0. Setting beta at 0.2, and
alpha at 0.05, and n1 = n2, the following sample size re-
quirements were estimated for changes from baseline at
12 months (Table 1).
Thus, 98 participants recruited, (assuming 20 % attri-
tion), would provide 78 participants at 12 months, as re-
quired by the smaller ES hypothesized for HbA1c. Based
on our pilot work, we estimated we would need to
screen approximately 500 participants by phone, and
125 in person, to enroll approximately 100 eligible/inter-
ested participants. We anticipated that our loss to
follow-up would actually be less than 20 %.
Recruitment strategies
Participants were recruited via general practitioner refer-
ral, targeted mail-outs, advertisements in local newspa-
pers and seniors’ magazines and from brochures
distributed to local medical practitioners and pharma-
cies. Participants were recruited from August 2006 to
December 2010 with the final 12-month assessment in
December 2011. Follow-up testing is due for completion
in February 2016.
Management
All incoming responses were recorded by the research
assistant and logged in a tracking database that outlined
the flow of participants through the recruitment, screen-
ing and (if eligible) intervention process.
Screening
Potential participants contacted the research assistant
and a telephone interview was conducted or scheduled
for a convenient time. The telephone screening was
comprised of questions to ascertain the participant’s
basic demographic and contact information, current dia-
betic and health status, medical history, current medica-
tion use and physical activity/exercise levels. The study
physician reviewed all of the individual screenings and
participants were subsequently notified of their eligibil-
ity. If eligible, participants were requested to attend the
University of Sydney for subsequent testing (including a
health and physical examination by a physician and a
12-lead electrocardiogram (ECG) and maximal exercise
stress test) to determine their eligibility.
Participants
Eligibility criteria for participants
The inclusion and exclusion criteria are listed in Fig. 1.
Participants eligible for inclusion were treated with
diet alone, oral medications or insulin or combin-
ation at the time of enrollment. Metabolic syndrome
was defined according to the International Diabetes
Federation as:
 Central obesity (defined as waist circumference ≥
94 cm for Europid men and ≥ 80 cm for Europid
women, plus any 2 of the following 4 factors:
 Raised TG level: ≥ 1.7 mmol/L, or specific treatment
for this lipid abnormality
 Reduced HDL cholesterol: < 1.03 mmol/L) in men
or < 1.29 mmol/L in women, or specific treatment
for this lipid abnormality
 Raised resting blood pressure: systolic blood
pressure (BP) ≥ 130 mmHg or diastolic BP ≥
Table 1 Primary outcomes and effect sizes
Primary outcome Experimental mean change Sham control Mean change Pooled standard deviation Effect size (d) Sample required
(total cohort)
HOMA2-IR −0.6 0 0.8 0.75 52
HbA1c (mmol/mol) −13.1 0 18.6 0.70 78
Sample size estimates were driven by hypothesized differences between the experimental and control participants in the primary outcomes of the trial: insulin
resistance and glucose homeostasis, as measured using HOMA2-IR and HbA1c respectively. Effect sizes were calculated based on an average of published studies
of PRT in diabetes/obesity [6, 26].
HbA1c glycosylated hemoglobin, HOMA2-IR homeostatic model of assessment of insulin resistance 2
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85 mmHg, or treatment of previously diagnosed
hypertension
 Raised fasting plasma glucose (FPG) ≥ 5.6 mmol/L,
or previously diagnosed T2D.
Exclusion criteria included significant cognitive im-
pairment (inability to comprehend informed consent or
evidence of functional impairment related to cognition
on screening), non-ambulatory status or lower extremity
amputation other than toes, current alcohol or substance
abuse, inability to comply with study requirements over
the course of 1 year due to travel plans or other commit-
ments, or specific contraindications to resistance train-
ing exercise, such as unstable cardiovascular disease,
aortic aneurysm, proliferative diabetic retinopathy,
uncontrolled hypertension, or rapidly progressive or
Fig. 1 Inclusion and exclusion criteria. BMI body mass index, PRT progressive resistance training, T2D type 2 diabetes
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terminal illness. Temporary exclusions included recent
laser or other ocular surgery (within 2 weeks), symptom-
atic hernias, acute illness, or recent fracture or other
injury, until resolved.
Settings and location where data were collected
All assessments were carried out at the University of
Sydney, Faculty of Health Sciences, Lidcombe and in the
Radiology Department of Royal Prince Alfred Hospital,
Sydney. Training sessions were conducted at the
Harbord Diggers’ Freshwater Fitness Center, Harbord
and at The Center for STRONG Medicine, Balmain
Hospital, Balmain.
Interventions
Experimental intervention: power training
Experimental participants performed power training
3 days per week and using 8 major muscle groups on
pneumatic resistance under supervision. We used a ver-
sion of PRT called power training, in which the concen-
tric contraction (lifting the weight) was done as fast as
possible, and the lowering of the weight was done slowly
(over 2–3 seconds). The exercises targeted the majority
of the large muscle groups of the arms, legs, and trunk
and consisted of lateral pulldown, chest press, upper
back, leg press, knee extension, and knee flexion, hip ex-
tension and hip abduction. These are symmetrical
muscle groups and functionally relevant to the activities
of daily living, gait, and balance of older adults. For each
exercise, participants performed 3 sets of 8 repetitions
with a fast concentric and slow eccentric phase on
pneumatic resistance training machines (approximately
6 seconds per repetition with 2 minutes of rest between
sets), a regimen which has been shown to produce
optimum adaptations in terms of muscle power, strength,
endurance in older adults [16].
The intensity was set at 80 % of the most recently deter-
mined peak strength (1 repetition maximum or 1RM). Re-
sistances used were increased as tolerated using the Borg
Scale Rating of Perceived Exertion [28, 29] on a continu-
ous basis throughout the 12 months, and 1RM testing was
repeated at 2-week intervals to ascertain progress and
regulate intensity. All training was fully supervised by
skilled exercise physiologists to maintain proper intensity
and progression, as 2 separate trials in T2D have now
shown that metabolic benefits of PRT disappear when par-
ticipants are switched to semi-supervised community-
based or home-based training [30, 31]. This was attributed
to a drop in adherence and intensity when supervision
was withdrawn. As this is a first-time efficacy trial of
power training, our intent was to maximise protocol
adherence.
Control group intervention: sham PRT
The same trainers supervised sham exercise control par-
ticipants in the same facility but at different hours to
avoid contamination and unblinding. These participants
performed three sets of eight repetitions on the same
machines, with no loading beyond the weight of the bar
of the machine, using slow concentric and eccentric
contraction speed. No interim 1RM testing and no pro-
gression took place. We have found that similar regi-
mens do not improve muscle function or mass,
functional status, mobility, depression, aerobic capacity,
or other clinical outcomes we are measuring [32, 33].
Low-intensity resistance training has also been shown to
have no effect on visceral fat [34], adiponectin [35], glu-
cose homeostasis or insulin sensitivity, or bone mineral
density [36], thus providing an ideal sham exercise con-
trol condition.
Outcomes
The primary outcomes of this study were insulin resist-
ance 96 hours after the last exercise bout as assessed by
the homeostatic model assessment 2 (HOMA2) com-
puter model and HbA1c. The 96-hour time interval for
HOMA2 was chosen to minimize the well-described
acute bout effect of exercise on insulin sensitivity, as we
are primarily interested in long-term training adapta-
tions related to visceral fat/muscle mass.
Secondary outcomes and covariates include all of the
components of metabolic syndrome, body composition,
adipokines, muscle morphology and metabolism,
genetic and epigenetic markers related to metabolic/
cardiovascular health and exercise adaptation, mea-
sures of energy expenditure and fat oxidation, neuro-
psychological function, cardiovascular health status,
quality of life, dietary intake and habitual physical
and sedentary activity levels. Blinded assessors, at a
laboratory facility separate from the training site to
prevent unblinding, repeated all measurements at
baseline, 6 months, and 12 months in experimental
and control participants. In addition, selected mea-
sures were repeated annually during the 5 additional
years of follow-up.
Domains of assessment
All outcome measures administered by blinded assessors
at baseline, 6-month and 12-month follow-up are listed
in Table 2. During the intervention phase, assessments
were conducted over 3 different days to allow for the
correct timing of exercise bouts and blood draws and to
ensure adequate participant preparation (e.g. the cessa-
tion of blood thinning medication where possible).
Figure 2 details the timing of assessments throughout
the course of the study.
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Table 2 Outcome measures
Outcome Outcome measure Description
Primary Insulin sensitivity 72 hours and 96 hours post exercise
• HOMA2 computer model for insulin sensitivity (IR, %S) [53]
• HOMA2 computer model for beta cell function (%Beta)




Diabetic medication inventory and dosages
Meal tolerance test
Secondary Cardiovascular health Resting heart rate variability and pulse wave velocity (arterial stiffness)
24-hour ambulatory blood pressure
Postural blood pressure
Ankle brachial blood pressure index
Lipid metabolism Total cholesterol
Low/High-density cholesterol
Triglycerides
Basal fat oxidation via indirect calorimetry
Intramuscular lipid content
Muscle morphology and metabolism Muscle tissue biopsy (vastus lateralis) [54]
• Glucose transporter type 4 receptor protein
• Intramuscular insulin-like growth factor 1
• Glycogen content
• Muscle fiber cross-sectional area
• Muscle fibrertyping
Adipokines and Inflammatory markers Adipose tissue biopsy [54]
• TNF-α
• Interleukin-6
• High molecular weight adiponectin
• C-Jun N-terminal kinase
• Serum C-reactive protein [55]
Body composition [53] Bioelectrical impedance analysis
• Skeletal muscle mass, skeletal muscle mass index
• Fat free mass
• Fat mass
• Body fat percentage
Computed tomography scan
• Abdominal and thigh girth, sagittal diameter
• Abdominal total, visceral and subcutaneous fat area
• Thigh total, intramuscular and subcutaneous fat area and muscle density
(intramuscular lipid index)
• Thigh muscle area
Waist circumference
Body mass index
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Randomization
Sequence generation
A computerized random-number generator (http://
www.randomization.com, created by Dr Gerard E. Dallal,
Tufts University) was used to randomize eligible partici-
pants at the level of the individual participant, stratified
by sex and use of insulin, in blocks of four.
Allocation concealment
Sealed envelopes were prepared by an independent re-
searcher, containing sequential treatment assignments
based on a computer-generated randomization scheme,
and opened by the participant’s trainer after completion
of all baseline testing.
Implementation
The study was approved by the University of Sydney and
the Sydney South West Area Health Service Human
Research Ethics Committees (RPA HREC protocol num-
ber × 04-009602/08/2006). A blinded outcomes assessor
obtained informed consent from all participants enrolled
in the study and informed the independent researcher
Table 2 Outcome measures (Continued)
Exercise capacity and Functional status Exercise stress test (maximal treadmill test with indirect calorimetry)
• Peak aerobic capacity
• Anaerobic threshold
• Oxygen uptake efficiency slope
• Heart rate recovery
Muscle strength, power and endurance
Habitual and maximal gait speed
Static and dynamic balance
Chair stand and stair climb power
Neuropsychological profile Geriatric Depression Scale
Pittsburgh Sleep Quality Index
Ewart’s Self-efficacy Scale
Cognitive function
• Mini Mental State Exam
• Word List Recognition and Recall
• Trail Making A and B
Actigraph sleep architecture over 7 days
• Total time in/out of bed
• Sleep latency, sleep efficiency
• Total time asleep
• Number of awakenings
Health-related quality of life Medical Outcomes Study 36-Item Short-Form Health Survey
Nutritional intake Food frequency questionnaire of Bloch over past 4 months
Energy expenditure Resting metabolic rate via indirect calorimetry
Habitual physical activity and sedentary behaviour via Physical Activity
Scale for the Elderly
Actigraph accelerometers over 7 days
• Waking hours
• Wear time
• Total sedentary time, mean sedentary time, median sedentary time
• Percentage of time spent in sedentary (1 MET), light (<3 MET), moderate (3–6 MET)
and vigorous (>6 MET) activity
• Total energy expenditure spent in sedentary (1 MET), light (<3 MET), moderate
(3–6 MET) and vigorous (>6 MET) activity
• Physical activity level (PAL score)
%S percent sensitivity, HOMA2 homeostatic model assessment 2, MET metabolic equivalent of task, TNF-α tissue necrosis factor alpha
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when the participant was eligible for randomization
(after completion of baseline testing). Participants were
notified of their training session time by the exercise
physiologist administering the intervention.
Blinding
This is the first truly double-blind sham exercise-
controlled RCT in T2D. All outcomes assessors were
blinded to treatment assignment for the duration of the
study. Only the exercise physiologists and medical prac-
titioners responsible for administering and overseeing
the exercise programs were informed of participant
group assignment. Participants were also blinded to the
investigators’ hypothesis and only informed of their
training time, not group assignment as active or sham,
and were told that two different kinds of exercise were
being compared for efficacy.
Statistical methods
All outcomes will be analyzed using all available data
without imputation for missing time points via repeated
measures linear mixed models, without regard to discon-
tinuation or dropout. Secondary per-protocol analyses
will be carried out on participants with ≥ 70 % compli-
ance to exercise. All mixed models will be adjusted for
relevant covariates if necessary, with group by time
interaction as the primary outcome of interest. Covari-
ates will be chosen as appropriate via a priori
Fig. 2 Timeline of assessments. a 6-month and 12-month assessments performed 72 hours after previous training session. b 6-month and 12-
month assessments performed 48 hours after previous training session. c 6-month and 12-month assessments performed 96 hours after previous
training session. 1RM 1 repetition maximum, 6MWT 6-Minute Walk Test, BP blood pressure, CT computed tomography, ECG electrocardiogram,
SF-36 36-Item Short-Form Health Survey, NHANES National Health and Nutrition Examination Survey
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hypothesized confounders if there are differences be-
tween groups within relevant variables at baseline within
the cohort despite randomization. Relationships between
variables of interest at baseline between changes scores
will be determined by simple and stepwise regression
models and logistic regression models as appropriate.
Statistical significance will be initially assumed at the
0.05 level, as all hypotheses were specified a priori,
and Bonferroni correction is considered overly conser-
vative in this instance [37]. Effect sizes and 95 % confi-
dence intervals (CIs) will be calculated for all
outcomes. Calculations of ES will be adjusted via
Hedges’ bias-corrected ES for small sample sizes [38]
and interpreted according to Cohen’s interpretation of
“trivial” (<0.20), “small” (≥0.20 < 0.50), “moderate”
(≥0.50 < 0.80), and “large” (≥0.80) ES [39]. Ninety-five
percent CIs for the relative ES will calculated. For ES
in non-normally distributed data, median will




Participants were assessed at baseline, 6 and 12 months
for the intervention phase of study and annually for the
remaining 5-years of follow-up. Figure 3 shows the flow
of participants through the study.
Recruitment
We assessed 427 people for eligibility (Fig. 3). After
completing the telephone screening questionnaire, 324
people were deemed ineligible for not meeting the inclu-
sion criteria (n = 285), declining to participate (n = 15),
and a further 24 people were either unable to commit,
had transport difficulties/did not live local to the train-
ing sites or had medical contraindications. A total of 103
people gave consent, met the eligibility criteria and
were randomized to either the power training inter-
vention group (n = 49) or the sham-exercise control
group (n = 54).
Losses and exclusions
Three participants withdrew from the study prior to
commencing the intervention. Fourteen participants
dropped out of the study (did not complete follow-up
assessments) after commencing the intervention (inter-
vention group n = 10; control group n = 4). One was an
adverse event related to the intervention (musculoskel-
etal injury in the intervention group), five felt the inter-
vention was too hard, four were medical concerns
unrelated to the intervention, three were due to commit-
ment issues, and one was due to disinterest. Our attri-
tion of 14 % at 12 months was less than expected for the
intervention period. As expected, there has been a
steady decline in participation over the follow-up phase.
A total of 70 people commenced the 5-year post-
intervention program with a total of 41 participants ex-
pected to complete the entire 6 years of follow-up.
Currently, 35 participants have completed the 6-year
follow-up, with the remaining 6 participants scheduled
for their final assessment.
Baseline demographics
The baseline participant characteristics are reported
in Table 3. Forty-nine and 54 participants were ran-
domized to the invervention and control groups, re-
spectively. Our eligibility criteria were designed so as
to maximize external validity as only terminal or un-
stable diseases, or conditions which would perman-
ently preclude resistance training, were exclusionary.
Thus, our cohort was generally representative of older
diabetic cohorts in Australia and other countries, with
multiple co-morbidities and chronic medication usage.
For example, the Australian Institute for Health and
Welfare 2007–8 [40] report states that 58 % of indi-
viduals with diabetes also have cardiovascular disease.
In our cohort, nearly one half (49 %) were being
treated for cardiovascular disease. Similarly, 43 % of
the Graded Resistance Exercise And Type 2 Diabetes
in Older adults (GREAT2DO) cohort had hyperchol-
esterolemia at baseline, which is not dissimilar to the
Australian adult population where half of all adults
over 25 years of age have high total cholesterol levels
(data from 1999–2000) [41]. Among the 103 partici-
pants in this study, only 5.8 % were current smokers,
similar to the 4.4 % reported in the Look AHEAD
study of adults with T2D in 2006 [42]. Sixteen partic-
ipants reported insulin use for control of their dia-
betes. In comparison to some previous trials that
have excluded people with cardiovascular disease and
insulin therapy, overall our cohort is more representa-
tive of the general population of older adults with
T2D.
Adverse events
There were eight adverse events in six participants ad-
judicated by the study physician to be related to study
procedures; seven in the intervention group and one
in the control group. These included three syncopal
episodes in a male participant with known syncope,
one hamstring strain, one back pain leading to drop-
out, one exacerbation of pre-existing umbilical hernia
requiring surgical repair, one subscapularis tear in a
female participant with pre-existing grade IV osteo-
arthritis/rotator cuff disease requiring surgery, and
one partial thickness tear of a rotator cuff muscle
managed conservatively.
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Discussion
We have shown for the first time that it is feasible to re-
cruit and retain older adults with T2D and multiple
chronic co-morbidities in a long-term trial of high-
intensity power training. Few RCTs of PRT, as an
isolated addition to usual care in middle-aged and older
adults with T2D, have been published: however, the
magnitude of change in glucose control (HbA1c) in
these studies was comparable to the effect of aerobic ex-
ercise or oral hypoglycemic therapy [3]. One study,
Fig. 3 Consolidated Standards of Reporting Trials (CONSORT) flow chart, Loss to follow-up and deceased numbers are cumulative. The numbers
for missed assessments are specific to each time point. A linear mixed-effects model with repeated measures will be used to determine changes
over time as this method allows for all available data to be used without imputation for missing values. Thus, even with dropouts, all participants
who entered the study at baseline will be entered into the model
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Table 3 Baseline participant characteristics
Power Sham Total
(n = 49) (n = 54) (n = 103)
Demographics
Age (years) 66.9 ± 4.7 68.8 ± 6.1 67.9 ± 5.5
Sex (female) 24.0 (49.0) 27.0 ± (50.0) 51.0 ± 0.5
Smoking status
Current 3.0 (6.1) 3.0 (5.6) 6.0 (5.8)
Past 31.0 (63.3) 33.0 (61.1) 64.0 (62.1)
Ethnic origin
Caucasian 49.0 (100.0) 50.0 (92.6) 99.0 (96.1)
Asian 0.0 (0.0) 2.0 (3.7) 2.0 (1.9)
Indian 0.0 (0.0) 2.0 (3.7) 2.0 (1.9)
Chronic diseases
Duration of diabetes (years) 6.9 ± 5.1 9.1 ± 6.7 8.0 ± 6.0
Number of chronic diseases 5.1 ± 1.9 5.1 ± 1.8 5.1 ± 1.8
Chronic diseases
Hypertension 37.0 (75.5) 39.0 (72.2) 76.0 (73.8)
Osteoarthritis 35.0 (71.4) 33.0 (61.1) 68.0 (66.0)
Cardiovascular diseases 23.0 (46.9) 27.0 (50.0) 50.0 (48.5)
High cholesterol 24.0 (49.0) 21.0 (38.9) 45.0 (43.7)
Cancer 14.0 (28.6) 17.0 (31.5) 31.0 (30.1)
GERD (Reflux/Barrett’s esophagus) 8.0 (16.3) 14.0 (25.9) 22.0 (21.4)
PVD 10.0 (20.4) 11.0 (20.4) 21.0 (20.4)
IHD, MI, Angina 8.0 (16.3) 11.0 (20.4) 19.0 (18.4)
Sleep apnea 7.0 (14.3) 12.0 (22.2) 19.0 (18.4)
Depression 10.0 (20.4) 8.0 (14.8) 18.0 (17.5)
Hypothyroidism 7.0 (14.3) 9.0 (16.7) 16.0 (15.5)
Arrhythmia 8.0 (16.3) 6.0 (11.1) 14.0 (13.6)
Ulcers (gastrointestinal tract) 7.0 (14.3) 7.0 (13.0) 14.0 (13.6)
Osteoporosis/Osteopenia 5.0 (10.2) 8.0 (14.8) 13.0 (12.6)
Gout 7.0 (14.3) 5.0 (9.3) 12.0 (11.7)
Benign prostatic hyperplasia 3.0 (6.1) 8.0 (14.8) 11.0 (10.7)
Chronic venous disease 4.0 (8.2) 6.0 (11.1) 10.0 (9.7)
COPD/CAL 2.0 (4.1) 7.0 (13.0) 9.0 (8.7)
Hyperthyroidism 2.0 (4.1) 6.0 (11.1) 8.0 (7.8)
Esophagitis 5.0 (10.2) 3.0 (5.6) 8.0 (7.8)
Health status
Weight (kg) 89.5 ± 15.2 88.8 ± 18.8 89.1 ± 17.1
BMI (kg/m2) 31.5 ± 4.7 31.6 ± 6.0 31.6 ± 5.4
Waist circumference (cm)
Men 112.4 ± 9.6 109.3 ± 11.5 110.8 ± 11.7
Women 109.6 ± 9.6 108.7 ± 11.5 109.1 ± 12.6
Resting blood pressure (mmHg)
Systolic 147.2 ± 17.9 145.1 ± 17.9 146.1 ± 17.9
Diastolic 78.9 ± 7.5 77.4 ± 10.2 78.1 ± 9.0
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which directly compared isolated PRT to aerobic exer-
cise in middle-aged type 2 adults with diabetes [26],
found that PRT significantly improved 48-hour continu-
ous glucose control, HbA1c, insulin sensitivity, and
lipids, whereas aerobic exercise was ineffective. Limita-
tions of previous studies of PRT include small sample
sizes and relatively short periods of follow-up in some
cases, and lack of comprehensive assessment of mecha-
nisms of benefit, cardiovascular profile and associated
clinical benefits relevant to older adults.
Thus, despite the strong theoretical rationale for its
use in this cohort, and its recent advocacy by expert
consensus panels internationally [1, 14, 43], PRT is
not a common treatment for diabetes [2] and more
evidence of feasibility, safety, and efficacy are needed.
This need is highlighted by the results of the Look
AHEAD trial, which reported no difference in the pri-
mary outcome of cardiovascular events following life-
style modification in type 2 diabetics, despite clear
benefits in secondary outcomes such as weight, phys-
ical activity level, fitness, quality of life, depression
levels and metabolic risk [44–46]. However, most life-
style interventions, even intensive ones such as Look
AHEAD, may not attenuate losses of lean tissue mass
seen with both aging and caloric restriction. In fact,
bone losses were greater in men in the intensive life-
style group in Look AHEAD compared to controls,
and were proportional to weight loss achieved [47, 48].
This important issue of lean tissue loss accompanying
lifestyle modification programs that do not prioritize
or include anabolic exercises thus requires additional
study, and is the focus of the GREAT2DO trial de-
scribed here.
Conclusion
To our knowledge no study investigating high-intensity
power training has yet been published, and thus the
GREAT2DO study will provide the first evidence of the
safety, efficacy and long-term feasibility of this novel
modality of anabolic exercise in older adults with T2D.
Other studies suggest that power training is useful for
osteoporosis [49, 50], balance [51], functional perform-
ance [18] and quality of life [52]. If our hypotheses are
correct, improvement in metabolic health and other sec-
ondary outcomes from this trial may add to the growing
rationale for this unique and robust form of exercise
training for the treatment of chronic disease-related and
age-related syndromes.
Table 3 Baseline participant characteristics (Continued)
Resting heart rate (bpm) 65.2 ± 12.1 64.6 ± 8.4 64.9 ± 10.2
Fasting glucose (mmol/L) 7.4 ± 2.5 7.1 ± 2.2 7.3 ± 2.4
Fasting insulin (mU/L) 10.1 ± 5.9 11.1 ± 6.7 10.6 ± 6.3
HbA1c (%) 6.9 ± 0.9 7.3 ± 1.3 7.1 ± 1.1
HOMA2-IR 2.6 ± 1.0 2.9 ± 1.3 2.7 ± 1.1
Cholesterol (mmol/L)
Total 4.5 ± 1.1 4.2 ± 1.1 4.4 ± 1.1
HDL 1.2 ± 0.3 1.2 ± 0.4 1.2 ± 0.3
LDL 2.5 ± 0.9 2.3 ± 0.9 2.4 ± 0.9
Triglycerides 1.7 ± 1.0 1.7 ± 0.9 1.7 ± 0.9
C-reactive protein (mg/L) 3.8 ± 3.2 4.5 ± 4.9 4.2 ± 4.2
Diabetic treatment
Diet only 8.0 (16.0) 10.0 (19.0) 18.0 (17.0)
Oral hypoglycemics only 34.0 (69.0) 35.0 (65.0) 69.0 (67.0)
Oral hypoglycemics and Insulin 4.0 (8.0) 7.0 (13.0) 11.0 (11.0)
Insulin only 3.0 (6.0) 2.0 (4.0) 5.0 (5.0)
Physical Function
Habitual gait speed (m/s) 1.2 ± 0.2 1.2 ± 0.2 1.2 ± 0.2
Maximal gait speed (m/s) 1.9 ± 0.3 1.9 ± 0.3 1.9 ± 0.3
6MWT (m) 551.1 ± 93.8 539.1 ± 95.3 544.8 ± 94.3
Values are means ± SD or n (%)
6MWT 6-Minute Walk Test, BMI body mass index, BPH benign prostatic hyperplasia, COPD/CAL chronic obstructive pulmonary disease/chronic airflow limitation,
GERD gastro-esophageal reflux disease, HbA1c glycemic control, HDL high-density lipoprotein, HOMA2-IR homeostatic model assessment 2, IHD ischemic heart
disease, LDL low-density lipoprotein, MI myocardial infarction, PVD peripheral vascular disease,
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